Starton
STAStarton Holdings is a clinical-stage biotechnology company that utilizes a proprietary continuous delivery platform to enhance the efficacy and tolerability of established FDA-approved therapies.
Starton has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
Starton Holdings is a clinical-stage biotechnology company that utilizes a proprietary continuous delivery platform to enhance the efficacy and tolerability of established FDA-approved therapies. The company focuses on treating hematologic malignancies by maintaining consistent therapeutic blood levels, thereby reducing the toxicity associated with traditional oral dosing peaks. Its primary value proposition lies in transforming acute cancer treatments into manageable chronic conditions through precision-targeted subcutaneous and oral controlled-release formulations.
Starton is a pioneer in continuous delivery for IMiDs, leveraging the 505(b)(2) pathway to reduce development risk while seeking market exclusivity through orphan drug and breakthrough designations.
Questions, answered.
- Who are Starton's competitors?
- Starton's key competitors include Johnson & Johnson, Bristol Myers Squibb, AbbVie, and others. These companies compete in similar markets and product categories.
- Who does Starton partner with?
- Starton's notable partners include ICON plc, Smiths Medical, Bristol Myers Squibb.
- Where is Starton headquartered?
- Starton is headquartered in United States of America.